The announcement of successful Phase 2 trial results typically leads to increased investor confidence and can significantly impact a biotech company's stock price. Given the positive outcome of FXR314's trial, demonstrating a statistically significant reduction in liver fat content, this is likely to be viewed positively by investors, potentially leading to a short-term increase in Organovo's stock price.